InsiderTrades

Form 4 for BBIO BridgeBio Pharma, Inc.

Accepted 2025-01-30 00:00:00 ET · period of report 2025-01-28 · accession 0000950170-25-011242 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DT 2025-01-30 2025-01-28 BBIO STEPHENSON BRIAN C CFO, Sec, Treas S - Sale+OE $36.29 -68.0K 93.8K -42% -$2.47M
DT 2025-01-30 2025-01-28 BBIO STEPHENSON BRIAN C CFO, Sec, Treas M - OptEx $17.00 +68.0K 161.8K +73% +$1.16M
DT 2025-01-30 2025-01-28 BBIO STEPHENSON BRIAN C CFO, Sec, Treas M - OptEx $0.00 -68.0K 448.7K -13% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-01-28 S D 68,000 $36.29 93,758 D — — (F2) Represents the weighted average sale price of the shares sold from $35.75 to $36.71 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
2 Common Common Stock 2025-01-28 M A 68,000 $17.00 161,758 D — —
3 Derivative Stock Option (right to buy) 2025-01-28 M D 68,000 $0.00 448,670 D $17.00 · — to 2029-06-26 68,000 Common Stock (F3) The shares subject to this option vested in 48 equal monthly installments from June 26, 2019 to June 26, 2023.